Ridinilazole, a narrow spectrum antibiotic for treatment of <i>Clostridioides difficile</i> infection, enhances preservation of microbiota-dependent bile acids
Xi Qian, Karin Yanagi, Anne Kane, Nicholas Alden, Ming Lei, David R. Snydman, Richard Vickers, Kyongbum Lee, Cheleste M. Thorpe
2020American Journal of Physiology-Gastrointestinal and Liver Physiology39 citationsDOIOpen Access PDF
Abstract
This is the first study to demonstrate in humans the relationships between Clostridioides difficile antibiotic treatment choice and bile acid metabolism both during therapy and after treatment cessation. The results show a microbiota- and metabolome-preserving property of a novel narrow-spectrum agent that correlates with the agent’s favorable sustained clinical response rates compared with broad-spectrum antibiotic treatment.
Topics & Concepts
AntibioticsDysbiosisClostridioidesBile acidInternal medicineVancomycinGut floraGastroenterologyClostridium difficileMedicineMicrobiologyBiologyBacteriaImmunologyStaphylococcus aureusGeneticsClostridium difficile and Clostridium perfringens researchGut microbiota and healthMicroscopic Colitis